Drug intelligence / Profile preview

antagomir-21

Development stage
Unknown
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intrathecal, Intranasal, Ophthalmic, Intraperitoneal
01

Overview

Antagomir-21 is a chemically modified antisense oligonucleotide designed to silence microRNA-21 (miR-21), a potent oncogenic and pro-inflammatory microRNA. Antagomirs are typically characterized by 2'-O-methyl modifications and a cholesterol conjugate at the 3' end to enhance cellular uptake and stability. By binding to miR-21, antagomir-21 prevents it from repressing its target mRNAs, such as PTEN, PDCD4, and SPRY2. This inhibition has been explored in various preclinical models for its potential to suppress tumor growth, reduce inflammation in autoimmune diseases like lupus and Crohn's disease, and promote tissue repair in conditions like spinal cord injury and acute kidney injury.

Other names
miR-21 inhibitormiR21 inhibitormiR 21 inhibitoranti-miR-21anti-miR21anti-miR 21microRNA-21 antagonistmicroRNA21 antagonistmicroRNA 21 antagonist
02

Targets

miR-21 (MicroRNA-21)

Beyond the preview

Go deeper on antagomir-21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on antagomir-21.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call